+ More
 News Room
 Contact Us
Home \ + More \ Newsroom

News & Events


GlySens Discusses its Long Term Fully Implantable Glucose Monitoring System at 4th Annual NIH Artificial Pancreas Workshop Patient Enrollment and Implantation Procedures Complete for FIGS-2 Trial
Bethesda, MD - July 6, 2016  – GlySens Incorporated’s presentation entitled “Continuous, Long-term, Fully Implanted Glucose Sensor” was discussed today by Dr. Joseph Lucisano, the Company’s founder and CTO, at the “Fourth Artificial Pancreas Workshop.” This event, held at the National Institutes of Health (NIH) campus, is organized in coordination with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Diabetes Mellitus Interagency Coordinating Committee (DIMCC). The ...
Read More>
Successful Re-implantation of the Eclipse® ICGM® Sensor in Sixth Clinical Trial Participant
SAN DIEGO, CA - March 14, 2016 – GlySens Incorporated today completed the successful re-implantation of the Eclipse® ICGM® Sensor in a sixth human subject participating in the Function of Implanted Glucose Sensor 2 (FIGS-2) trial [Clinicaltrials.gov NCT02345967] for people with diabetes in the United States. The FIGS-2 study is a multi-center, long- term assessment of the Eclipse ICGM Sensor.
Read More>
GlySens Incorporated Secures $20M Series D Investment to Advance its Fully Implanted, Long-Term Continuous Glucose Monitoring System
SAN DIEGO, CA - January 5, 2016 /PRNewswire/ – GlySens Incorporated announced today that it has closed a $20M Series D financing led by prior investors from its Series C round, in addition to significant participation from new investors.
“The clinical performance of our fully implanted ICGM® system, now with multiple patients approaching 12 months of in-vivo use, was instrumental in our ability to secure incremental funding on terms highly supportive of the Company’s long term vision and...
Read More>


GlySens Incorporated Secures FDA Approval to Extend Second Generation Fully-Implanted CGM Sensor Evaluation from 6 to 12 Months
SAN DIEGO, CA - August 17, 2015 /PRNewswire/ GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM® System) from the originally approved six-month duration to the system’s commercially-intended operational duration of twelve months. “We very much appreciate the timely review and approval by FDA of our request to extend the duration of this clinical evaluation, and are...                           
Read More>
GlySens Incorporated Names William Markle Chief Executive Officer
SAN DIEGO, CA - April 2, 2015 /PRNewswire/ – GlySens Incorporated announced today that William H. Markle has been selected to join the Company as President and Chief Executive Officer. Mr. Markle succeeds founder and current CEO Joseph Lucisano, PhD, who will continue to lead the Company’s development efforts as Chief Technology Officer. Mr. Markle has distinguished himself in a successful 25-year career in the medical device field and was formerly founder, President, and CEO of GluMetrics, Inc. At...                                               
Read More>
GlySens Incorporated Secures $12M Series C Investment Proceeds dedicated to advanced product commercialization steps
SAN DIEGO, CA - January 5, 2015 /PRNewswire/ – GlySens Incorporated announced today that it has closed a $12 million dollar Series C investment round, which included participation from several new investors as well as a group of returning investors that had previously participated in the Company’s Series B financing. The Company will utilize the proceeds from the new investment to advance the development of its ICGM® continuous glucose monitoring system for people with diabetes. This system includes...                         
Read More>
3931 Sorrento Valley Blvd
Suite 110
San Diego, CA 92121
Ph:  +1 (858) 638-7708
Fax: +1 (858) 638-7727

TechnologyNews RoomCareersContact Us

© 2018 GlySens Incorporated. All Rights Reserved.
GlySens®, Eclipse®, and ICGM® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
 Terms of Use Privacy Policy